BioSynchronicity Corporation

BioSynchronicity Corporation is a diagnostic test manufacturer specializing in rapid, point-of-care in vitro immunochromatographic assays for infectious disease detection. The company's primary product is the C-Sync® COVID-19 Antigen Test, an ultra-rapid qualitative assay for SARS-CoV-2 detection authorized under FDA Emergency Use Authorization (EUA220346, issued March 23, 2023). The company also develops the Stayin' Alive™ product line, including multi-drug screening tests. BioSynchronicity operates a team with expertise in technology development, healthcare delivery, and international trade, supported by state-of-the-art R&D capabilities. Manufacturing is conducted under ISO 13485 certified protocols with quality control and assurance supervision. Analytical performance testing is performed by an accredited laboratory in Rockville, Maryland. The company holds CE Mark certification for the European Union with Ministry of Health registration in The Netherlands, and has obtained a Free Sales Certificate for the UAE. BioSynchronicity is positioned to serve markets across the USA, Europe, MENA, and Africa. The company emphasizes affordable, reliable rapid diagnostic testing as a component of integrated infectious disease mitigation strategies.